Lung cancer
Conditions
Interventions
None listed
Sponsors
National Health Organization Kyoto Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Pathologically confirmed the diagnosis of non-small cell lung cancer Advanced (unresectable) or recurrent after resection Refractory to one or more chemotherapeutic regimens and planned to be treated with atezolizumab A score of ECOG-PS is 0 to 2 The findings which are suspicious to interstitial pneumonia such as reticular opacity or fibrotic change are observed in two or more lobes of the lung confirmed by the CT performed within one month until the initiation of atezolizumab.
Exclusion criteria
Exclusion criteria: Severe renal dysfunction (eGFR < 30 ml/min/1.73m2) Severe liver dysfunction (AST > 100 IU/ml, ALT > 100 IU/ml, or T-Bil > 3 mg/dl) Respiratory failure (PaO2 < 60 mmHg or PaCO2 >45 mmHg on under room air atmosphere) Prior history of acute exacerbation of interstitial pneumonia or drug-induced pneumonitis Impossibility to obtain a written consent form Impossibility to obtain sufficient data of outcomes Judgement of unsuitability as a subject from researchers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of drug-induced pneumonitis during the initial and one month after the last administration of atezolizumab | — |
Secondary
| Measure | Time frame |
|---|---|
| Response rate and disease control rate of atezolizumab Progression-free and overall survival time from the initiation of atezolizumab Incidences of any adverse events from the initiation of atezolizumab | — |
Countries
Japan
Contacts
Public ContactOsamu Kanai
National Health Organization Kyoto Medical Center Respiratory Medicine
Outcome results
None listed